Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results-Reference-Cited by-同舟云学术

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Published:2021-08 Issue: Volume: Page:
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Silverberg Jonathan I.,de Bruin-Weller Marjolein,Bieber Thomas,Soong Weily,Kabashima Kenji,Costanzo Antonio,Rosmarin David,Lynde Charles,Liu John,Gamelli Amy,Zeng Jiewei,Ladizinski Barry,Chu Alvina D.,Reich Kristian

Funder

AbbVie Inc

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference29 articles.

1. Atopic dermatitis;Weidinger;Nat Rev Dis Prim,2018

2. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions;Hay;J Invest Dermatol,2014

3. Atopic dermatitis: burden of illness, quality of life, and associated complications;Drucker;Allergy Asthma Proc,2017

4. The burden of atopic dermatitis: summary of a report for the National Eczema Association;Drucker;J Invest Dermatol,2017

5. Public health burden and epidemiology of atopic dermatitis;Silverberg;Dermatol Clin,2017

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib;Journal of Cutaneous Immunology and Allergy;2024-08-22

2. Revisiting immunotherapeutic strategies for the management of atopic dermatitis;Exploration of Asthma & Allergy;2024-08-09

3. Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review;PLOS ONE;2024-07-26

4. Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders;Clinical & Experimental Allergy;2024-07-24

5. Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China;Frontiers of Medicine;2024-07-16